Skip to content

Regeneron Pharmaceuticals

US · REGN #285 by market cap Listed 1970
920.69 -1.71 -0.19%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Recent news

  • Rating change
    Leerink Partners Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Announces Target Price $835
    Market Newswire · 2026/10/20
  • BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,050
    Market Newswire · 2026/11/19
  • Rating change
    Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $865
    Market Newswire · 2026/10/19
  • Form 144 | Regeneron Pharmaceuticals(REGN.US) Officer Proposes to Sell 4.77 Million in Common Stocks
    Market Newswire · 2026/11/18
  • Rating change
    BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $920
    Market Newswire · 2026/10/12
  • Rating change
    A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $982 to $1,175
    Market Newswire · 2026/11/3
  • Company notice
    LYC Healthcare: MEXTER TECHNOLOGY BERHAD (MEXTER) • PROPOSED ACQUISITION BY ITS 80% OWNED SUBSIDIARY MEXCOMM SDN BHD (777810-D) OF A 49% EQUITY INTEREST IN E-G6 SOLUTION (THAILAND) CO. LTD. (REGN NO. 0105551096920) (“THE COMPANY”) (“ACQUISITION”
    Bursa Malaysia · 2012/8/6
  • Rating change
    BofA Securities Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,030
    Market Newswire · 2026/11/11
  • Rating change
    BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,050
    Market Newswire · 2026/11/4
  • Rating change
    CCORF Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $922
    Market Newswire · 2026/10/28
  • Barclays Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,075
    Market Newswire · 2026/11/17
  • Rating change
    Scotiabank Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Maintains Target Price $770
    Market Newswire · 2026/10/14
  • Rating change
    UBS Initiates Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Announces Target Price $978
    Market Newswire · 2026/10/15
  • Rating change
    UBS Group: Resumes coverage of Regeneron Pharmaceuticals (REGN.US) with a "Buy" rating; blockbuster drug Dupixent's potential is undervalued
    Zhitong Finance · 2026/10/15
  • Rating change
    TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $980
    Market Newswire · 2026/10/21
  • Rating change
    UBS Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $978
    Market Newswire · 2026/10/16
  • CCORF Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,175
    Market Newswire · 2026/11/12
  • Rating change
    Leerink Partners Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Maintains Target Price $835
    Market Newswire · 2026/10/21
  • Rating change
    A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $825 to $1,050
    Market Newswire · 2026/10/31
  • Regeneron Pharmaceuticals(REGN.US) Officer Sells US$4.8 Million in Common Stock
    Market Newswire · 2026/11/19
  • Rating change
    BofA Securities Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $908
    Market Newswire · 2026/10/12
  • Regeneron Pharmaceuticals(REGN.US) Officer Sells US$4.31 Million in Common Stock
    Market Newswire · 2026/11/5
  • Regeneron Pharmaceuticals(REGN.US) Director Sells US$20.38 Million in Common Stock
    Market Newswire · 2026/11/5
  • Regeneron Pharmaceuticals(REGN.US) Director Sells US$7.59 Million in Common Stock
    Market Newswire · 2026/11/5
  • Regeneron Pharmaceuticals(REGN.US) Officer Sells US$3.83 Million in Common Stock
    Market Newswire · 2026/11/7

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:02:42 · For reference only, not investment advice and not tailored to your situation.

Regeneron Pharmaceuticals discussion 0 comments

Add a comment